Conclusion
GIST
Anlotinib showed moderate antitumor activity in drug-resistant GIST cell lines in vitro, and good PFS and better tolerance in second-line therapy study.This article reports on the inhibitory effect of anlotinib in GIST cell lines with different gene mutations, evaluating the efficacy and safety of second-line treatment of GIST with anlotinib compared with second-line treatment with sunitinib in the same period. The clinical trial registration number is NCT04106024.